Urinary N-acetyl-beta-d-glucosaminidase (NAG) with neutrophil gelatinase-associated lipocalin (NGAL) improves the diagnostic value for proximal tubule damage in diabetic kidney disease
Screening for diabetic kidney disease (DKD) remains a challenge; however, there has been an ongoing research to investigate the diagnostic value of different biomarkers to identify DKD. The aim of this study was to assess the diagnostic value of both N-acetyl-beta-d-glucosaminidase (NAG) and neutrophil gelatinase-associated lipocalin (NGAL) in the progression of DKD. This cross-sectional case–control study included 92 type 2 diabetic patients with or without DKD. Urinary NAG and NGAL were measured to evaluate their diagnostic values as biochemical markers related to DKD. Both urinary NAG and NGAL levels were significantly higher among patients with DKD. In multiple linear regression analysis, NAG showed a positive significant association with NGAL in the three different adjusted models, while no significant correlation with fasting blood glucose, glycated hemoglobin, serum creatinine, estimated glomerular filtration rate, and albumin creatinine ratio were observed. The area under the curve for NGAL was 0.659 (p = 0.01) and 0.564 (p = 0.297) for NAG in DKD patients. This study demonstrates the association between urinary NAG and NGAL as a tubular damage marker for DKD although longitudinal studies are needed to evaluate its diagnostic value.
KeywordsDiabetic kidney disease N-acetyl-beta-d-glucosaminidase Neutrophil gelatinase-associated lipocalin Albuminuria Tubular marker
The authors would like to acknowledge the research unit team, the hospitals involved in the study, and all staff nurses in different wards, for their participation in conducting the study. The authors would also like to acknowledge King Abdulaziz City for Science and Technology (KACST) for funding this project (grant for project no: A-T-34-194).
Compliance with ethical standards
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
- Ketteler M, Block GA, Evenepoel P et al (2018) Diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder: synopsis of the kidney disease: improving global outcomes 2017 clinical practice guideline update. Ann Intern Med 168:422. https://doi.org/10.7326/M17-2640 CrossRefPubMedGoogle Scholar
- Raosoft (2004) Sample size calculator. In: Sample size calc. raosoft Inc. http://www.raosoft.com/samplesize.html. Accessed 30 Dec 2018
- Sheira G, Noreldin N, Tamer A, Saad M (2015) Urinary biomarker N-acetyl-β-D-glucosaminidase can predict severity of renal damage in diabetic nephropathy. J Diabetes Metab Disord 14:. https://doi.org/10.1186/s40200-015-0133-6